What Doctors Look for in GLP-1 Candidates — Eligibility Criteria Explained

Not everyone who wants a GLP-1 medication is a good candidate for one. Before writing a prescription, physicians evaluate a specific set of clinical criteria — body mass index, metabolic history, contraindications, and treatment goals — to determine whether GLP-1 therapy is appropriate, safe, and likely to be effective.

Understanding what doctors look for can help you walk into your appointment prepared, or assess whether an online telehealth evaluation is thorough enough to trust.

BMI and Weight-Related Health Conditions

The primary eligibility threshold for GLP-1 prescriptions follows FDA labeling and clinical guidelines. Most physicians look for one of two criteria:

• BMI of 30 or higher (clinical obesity), or
• BMI of 27 or higher with at least one weight-related comorbidity — such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

Some telehealth platforms have begun evaluating patients with BMIs as low as 25 when metabolic risk factors are present, though this remains off-label for most approved GLP-1 indications.

Medical History and Contraindications

A responsible prescriber will screen for absolute contraindications before considering GLP-1 therapy. These include:

• Personal or family history of medullary thyroid carcinoma (MTC) — a rare thyroid cancer linked to GLP-1 receptor activation in animal studies.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — a genetic condition that increases MTC risk.
• History of pancreatitis — GLP-1 agonists may increase pancreatic inflammation risk in susceptible individuals.
• Known hypersensitivity to semaglutide, tirzepatide, or any formulation ingredient.

Relative contraindications — conditions that don't automatically disqualify you but require careful evaluation — include gastroparesis, severe gastrointestinal disease, gallbladder disease, and significant renal impairment.

Current Medications and Drug Interactions

Doctors review your full medication list for potential interactions. GLP-1 agonists slow gastric emptying, which can affect absorption of oral medications — particularly insulin, sulfonylureas, and oral contraceptives. Patients on blood thinners or diabetes medications may need dose adjustments during GLP-1 therapy.

Mental Health and Eating Behavior Assessment

Increasingly, clinicians evaluate psychological readiness for GLP-1 therapy. Active eating disorders (particularly bulimia or binge-eating disorder under inadequate treatment), severe untreated depression, or suicidal ideation require stabilization before initiating weight-loss pharmacotherapy. A good prescriber asks about your relationship with food — not just your weight.

Baseline Lab Work

While not universally required, many physicians order baseline labs before prescribing:

• HbA1c and fasting glucose (metabolic status)
• Lipid panel (cardiovascular risk)
• Kidney function (eGFR, creatinine)
• Liver enzymes (ALT, AST)
• Thyroid function (TSH)

These establish a clinical baseline for monitoring treatment response and catching adverse effects early.

What This Means for Choosing a Provider

The quality of your initial evaluation directly correlates with the safety and effectiveness of your treatment. Telehealth platforms that conduct comprehensive screenings — including medical history, medication review, and lab considerations — offer a standard of care comparable to in-person visits.